EUVIMEDEUVIMED entdecken
Multizentrische Studie

Cytologic features of differentiated high‐grade thyroid carcinoma: A multi‐institutional study of 40 cases

Vanda F Torous iD, Tikamporn Jitpasutham, Zubair Baloch, Richard L Cantley iD, Darcy A Kerr iD, Xiaoying Liu, Zahra Maleki iD, Ross Merkin, Vania Nosé, Liron Pantanowitz iD, Isabella Tondi Resta, Esther D Rossi iD und 1 weitere

Cancer Cytopathology · 2024-08 · 132 (8) · 525-536

DOI: 10.1002/cncy.22874 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Cytopathology, online erschienen am 14.06.2024. Verfasst von Vanda F Torous und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Differentiated high‐grade thyroid carcinoma (DHGTC) is recently recognized by the World Health Organization (WHO) as a subgroup of thyroid carcinomas with high‐grade features while retaining the architectural and/or cytologic features of well‐differentiated follicular–cell‐derived tumors. The cytomorphology of DHGTC is not well documented despite potential implications for patient triage and management.

Methods

The pathology archives of six institutions were searched for cases diagnosed on resection as “high‐grade thyroid carcinoma” using WHO criteria. The fine‐needle aspiration (FNA) cohort represents a 10‐year period (2013–2023); all were reviewed to confirm DHGTC classification. The corresponding FNAs were assessed for 32 cytomorphologic features.

Results

Forty cases of DHGTC with prior FNA were identified. The mean patient age was 64.2 years. The average lesion size was 4.9 cm, and the majority demonstrated a TI‐RADS score of 4 or 5 (95.2%). Three main high‐grade subsets of DHGTC based on corresponding histology included papillary thyroid carcinoma (65%), follicular carcinoma (22.5%), and oncocytic carcinoma (12.5%). Over 97% of FNA cases were classified as Bethesda category IV or above. Approximately 25% of DHGTC showed cytologic features that included marked cytologic atypia, increased anisonucleosis, large oval nuclei, mitotic activity, or necrosis ( p < .05); 68% of DHGTC cases were associated with high‐risk molecular alterations. TERT mutations occurred in 41%, of which 89% of these were associated with a second mutation, usually RAS or BRAF p .V600E.

Conclusions

Cytology has a low sensitivity for DHGTC, although a subset of DHGTCs have cytologic features raising the possibility of a high‐grade thyroid carcinoma. Other findings include high‐risk molecular changes and clinicopathologic features such as older patient age and larger lesion size.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsHumansMiddle AgedFemaleMaleBiopsy, Fine-NeedleAgedAdultNeoplasm GradingAdenocarcinoma, FollicularAged, 80 and overRetrospective Studies

Stichwörter der Autor:innen

BRAFFNARASTERThigh‐grademolecularpapillary thyroid carcinomapoorly differentiatedthyroid

Autor:innen und Institutionen

  • Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Pathology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
  • Department of Pathology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Pathology and Laboratory Medicine, Dartmouth Health and Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Vanda F Torous, Richard L Cantley, Darcy A Kerr, Zahra Maleki, Liron Pantanowitz, Esther D Rossi, William C Faquin

Zitieren

APA

Torous, V. F., Jitpasutham, T., Baloch, Z., Cantley, R. L., Kerr, D. A., Liu, X., Maleki, Z., Merkin, R., Nosé, V., Pantanowitz, L., Resta, I. T., Rossi, E. D., & Faquin, W. C. (2024). Cytologic features of differentiated high‐grade thyroid carcinoma: A multi‐institutional study of 40 cases. Cancer Cytopathology, 132(8), 525-536. https://doi.org/10.1002/cncy.22874

Vancouver

Torous VF, Jitpasutham T, Baloch Z, Cantley RL, Kerr DA, Liu X, et al. Cytologic features of differentiated high‐grade thyroid carcinoma: A multi‐institutional study of 40 cases. Cancer Cytopathology. 2024;132(8):525-536. doi:10.1002/cncy.22874

BibTeX
@article{Torous2024,
  author = {Torous, Vanda F and Jitpasutham, Tikamporn and Baloch, Zubair and Cantley, Richard L and Kerr, Darcy A and Liu, Xiaoying and Maleki, Zahra and Merkin, Ross and Nosé, Vania and Pantanowitz, Liron and Resta, Isabella Tondi and Rossi, Esther D and Faquin, William C},
  title = {Cytologic features of differentiated high‐grade thyroid carcinoma: A multi‐institutional study of 40 cases},
  journal = {Cancer Cytopathology},
  year = {2024},
  volume = {132},
  number = {8},
  pages = {525--536},
  doi = {10.1002/cncy.22874}
}
Kostenlos starten →